Guardian Pharmacy (NYSE: GRDN) hikes 2026 EBITDA outlook after strong 2025
Rhea-AI Filing Summary
Guardian Pharmacy Services reported strong 2025 results and raised its 2026 profit outlook. Revenue for 2025 grew to
For 2026, Guardian kept its revenue outlook at
Guardian highlighted operational gains, including the acquisition of North Ridge Pharmacy in Montana, vaccine volume growth with more than 120,000 residents vaccinated in 2025, and an annualized return on equity of about
Positive
- Return to profitability and stronger cash generation: 2025 revenue reached
$1.45 billion and net income attributable to the company improved to$48.96 million from a prior-year loss, with Adjusted EBITDA increasing to$115.15 million and operating cash flow rising to$100.29 million . - Raised 2026 Adjusted EBITDA guidance: The company increased its 2026 Adjusted EBITDA outlook to
$120–$124 million from$115–$118 million , signaling confidence in earnings power despite unchanged revenue guidance. - Stronger balance sheet and high ROE: Year-end cash and cash equivalents were
$65.6 million with no long-term debt outstanding on a$75 million credit facility, and annualized return on equity was about27% , highlighting capital efficiency.
Negative
- None.
Insights
2025 marked a major profitability swing and a higher 2026 EBITDA bar.
Guardian Pharmacy Services shifted from a sizeable 2024 loss to
The company raised its 2026 Adjusted EBITDA guidance to
Balance sheet strength is notable, with
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
On March 11, 2026, Guardian Pharmacy Services, Inc. issued a press release reporting its financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.
The information set forth under this Item 2.02 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| 99.1 | Press Release dated March 11, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Guardian Pharmacy Services, Inc. | ||||||
| March 11, 2026 |
By: | /s/ David K. Morris | ||||
| Name: | David K. Morris | |||||
| Title: | Executive Vice President and Chief Financial Officer | |||||
Exhibit 99.1
Guardian Pharmacy Services Reports Fourth Quarter and Full Year 2025 Financial Results; Raises 2026 Adjusted EBITDA Guidance
ATLANTA, March 11, 2026 – Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation’s leading long-term care (“LTC”) pharmacy services companies, announced today its financial results for the fourth quarter and full year ended December 31, 2025. The Company also raised its full-year 2026 Adjusted EBITDA guidance.
Fourth Quarter Financial Results
| • | Revenue of $397.6 million, up 17% year-over-year with organic growth of 12%. |
| • | Residents served ended the quarter at approximately 205,000, up 10% year-over-year. |
| • | Net Income of $21.3 million, up 81% from $11.8 million in the prior-year period. |
| • | Adjusted EBITDA of $39.5 million, up 53% year over year. |
| • | Diluted EPS of $0.33 for the quarter, with Adjusted EPS of $0.37.1 |
Full Year Financial Results
| • | Revenue of $1.45 billion, up 18% from $1.23 billion in the prior year period with organic growth of 13%. |
| • | Net Income (loss) of $49.0 million, compared to ($71.0) million in 2024. |
| • | Adjusted EBITDA of $115.1 million, up 27% compared to $90.8 million year over year. |
| • | Diluted EPS of $0.78, with Adjusted EPS of $1.071. |
| • | Cash and cash equivalents totaled $65.6 million at year end, up from $4.7 million at the end of 2024. |
CEO Commentary
“2025 was a year of broad-based execution and disciplined investment, with results that exceeded our expectations across resident, revenue, and Adjusted EBITDA growth,” said Fred Burke, President and CEO. “These results underscore the scalability of our platform and the dedication of our teams, who continue to deliver high-quality service and meaningful value to the residents and facility partners we serve.”
Burke continued, “We exited the year with strong momentum and are accordingly raising our outlook for 2026 Adjusted EBITDA in a measured manner, consistent with our philosophy of guiding to what we can clearly see. A portion of the upside we experienced in the fourth quarter relative to our prior guidance reflects favorable payor dynamics and normal quarter-to-quarter variability, which we have not incorporated into our outlook. We view the underlying run rate of the business exiting 2025 as generating approximately $110 million of Adjusted EBITDA, and are raising our 2026 outlook on that basis. As we enter the first quarter under the initial phase of new IRA drug pricing changes, we are maintaining our 2026 revenue outlook provided in mid-January. We remain confident in the durability of our operating model and our ability to deliver sustained, long-term value for our shareholders.”
| 1 | Diluted EPS and Adjusted EPS include dilutive shares related to restricted stock units and unvested Class A and Class B common stock. See reconciliation of Adjusted EPS to Diluted EPS, the most directly comparable GAAP measure, below. |
FY 2026 Outlook – Raising Adjusted EBITDA Guidance
The guidance below excludes future acquisitions.
| Updated Guidance | Previous Guidance | |||||||
| Revenue |
$1.40 billion – $1.42 billion | $1.40 billion – $1.42 billion | ||||||
| Adjusted EBITDA |
$120 million – $124 million | $115 million – $118 million | ||||||
Operational and Strategic Highlights
Acquisitions & Greenfields
During the quarter, Guardian acquired North Ridge Pharmacy, located in Missoula, Montana, bringing our full-service pharmacy count to 54.
Vaccine Clinics
Vaccine prescription volumes increased 3% year over year in the fourth quarter, while full-year prescription volumes increased 9%. Importantly, profitability improved compared to the prior year, driven by stronger purchasing, reimbursement, and labor economics as well as solid operational execution. In total, we vaccinated more than 120,000 residents in 2025.
Capital Efficiency and Liquidity
Guardian delivered an annualized return on equity2 of approximately 27% in 2025, reflecting the capital efficiency of the business. The Company ended the year with a strong liquidity position, including $65.6 million of cash and cash equivalents with no long-term debt outstanding under its $75 million credit facility.
Conference Call Details
Guardian will host a conference call to discuss these results today at 4:30 pm ET. The call can be accessed live by dialing (646) 564-2877 for U.S. participants, or +1 (800) 549-8228 for international participants, and referencing conference ID “93533,” or via audio webcast at https://investors.guardianpharmacy.com
About Guardian Pharmacy Services
Guardian Pharmacy Services is one of the nation’s leading long-term care pharmacy services companies. Through its locally-based business model, Guardian partners with long-term care facilities (“LTCFs”) to deliver medications and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. With a growing network of 61 pharmacies, 54 of which are full-service, Guardian is dedicated to providing exceptional service to approximately 205,000 residents (as of December 31, 2025).
Investor Contact:
Ashley Stockton
Vice President, Investor Relations
IR@guardianpharmacy.net
| 2 | Return on equity is calculated as Net Income of $49.0 million divided by Average Total Equity during the period of $184.0 million. Average Total Equity is calculated based on Total Equity of $150.0 million as of December 31, 2024 and Total Equity of $217.9 million as of December 31, 2025. |
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are all statements other than those of historical fact. Any statements about our expectations, beliefs, plans, predictions, forecasts, objectives, assumptions, or future events or performance are forward-looking. These statements are often, but not always, made through the use of words such as “aims,” “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “outlook,” “plans,” “projects,” “seeks,” “should,” “will,” “would,” and similar expressions. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements are not guarantees of future performance and involve risks and uncertainties which are subject to change based on various important factors, many of which are beyond our control. Such risks and uncertainties include: our ability to effectively execute our business strategies, implement new initiatives and improve efficiency; our ability to effectively market and sell, customer acceptance of, and competition for, our pharmaceutical and health care services in new and existing markets; our relationships with pharmaceutical wholesalers and key manufacturers, LTCFs and health plan payors; our ability to maintain and expand relationships with LTCF operators on favorable terms; the impact of a national emergency, public health crisis, global pandemic or outbreak of infectious disease on our employees and business and on our supply chain and the LTCFs we serve; continuing government and private efforts to lower pharmaceutical costs, including by limiting pharmacy reimbursements; changes in, and our ability to comply with, healthcare and other applicable laws, regulations or interpretations; further consolidation of managed care organizations and other health plan payors and changes in the terms of our agreements with these parties; our ability to retain members of our senior management team, our local pharmacy management teams and our pharmacy professionals; our exposure to, and the results of, claims, legal proceedings and governmental inquiries; our ability to maintain the security and integrity of our operating and information technology systems and infrastructure (e.g., against cyber-attacks); product liability, product recall, personal injury or other health and safety issues related to the pharmaceuticals we dispense; the impact of supply chain and other manufacturing disruptions or trade policies related to the pharmaceuticals we dispense; the sufficiency of our sources of liquidity and financial resources to fund our future operating expenses and capital expenditure requirements, and our ability to raise additional capital, if needed; the misuse or off-label use, or errors in the dispensing or administration, of the pharmaceuticals we dispense; and volatility of our stock price. We are subject to additional risks and uncertainties described in our periodic reports filed with the Securities and Exchange Commission from time to time, including in the “Risk Factors” section contained in our most recent Annual Report on Form 10-K, which report is publicly available at www.sec.gov and via our website, investors.guardianpharmacy.com Any forward-looking statements in this press release should be evaluated in light of these important risk factors. This press release reflects management’s views as of the date hereof. Except to the extent required by applicable law, Guardian undertakes no obligation to update or revise any information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise.
Additional Information
This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings. Copies of our reports are available on our website at no expense at investors.guardianpharmacy.com and through the SEC’s website at www.sec.gov.
Use of Non-GAAP Financial Measures
To supplement the results presented in our consolidated financial statements in accordance with generally accepted accounting principles in the United States (“GAAP”), we also present Adjusted EBITDA, Adjusted Net Income, Adjusted EPS and Adjusted SG&A, which are financial measures not based on any standardized methodology prescribed by GAAP.
We define Adjusted EBITDA as net income (loss) before interest expense, income taxes, depreciation and amortization, as adjusted to exclude the impact of items and amounts that we view as not indicative of our core operating performance, including share-based compensation, acquisition accounting adjustments, certain legal and regulatory items, financing-related and other activities, payor-reimbursement matters, and certain tax matters related to the Corporate Reorganization and IPO.
We define Adjusted Net Income as net income attributable to Guardian Pharmacy Services, Inc. before share-based compensation expense, certain legal and other regulatory items, financing-related and other activities, payor-reimbursement matters, amortization expense associated with acquisition-related intangible assets, the income tax impact of the adjustments, and certain tax matters related to the Corporate Reorganization and IPO.
We define Adjusted EPS as Adjusted Net Income divided by the total weighted average of diluted shares for Class A and Class B common stock.
We define Adjusted SG&A as GAAP selling, general, and administrative expenses adjusted to exclude the impact of share-based compensation, expenses relating to certain legal and regulatory items, financing-related and other activities, and payor-reimbursement matters.
Adjusted EBITDA, Adjusted Net Income, Adjusted EPS and Adjusted SG&A do not have a definition under GAAP, and our definition of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS and Adjusted SG&A may not be the same as, or comparable to, similarly titled measures used by other companies.
We use Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A to better understand and evaluate our core operating performance and trends. We believe that presenting Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A provides useful information to investors in understanding and evaluating our operating results, as it permits investors to view our core business performance using the same metrics that management uses to evaluate our performance.
There are a number of limitations related to the use of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A rather than the most directly comparable GAAP financial measure, including:
| • | Adjusted EBITDA does not reflect interest and income tax payments that represent a reduction in cash available to us; |
| • | Depreciation and amortization are non-cash charges and the assets being depreciated may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements; |
| • | Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS do not reflect changes in, or cash requirements for, our working capital needs; |
| • | Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A do not consider the impact of share-based compensation; and |
| • | Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A exclude the impact of certain legal and regulatory items, and payor-reimbursement matters which can affect our current and future cash requirements. |
Because of these limitations, Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. You should consider Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A alongside other financial measures, including net income, diluted EPS, GAAP selling, general, and administrative expense and our other financial results presented in accordance with GAAP.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures, are set forth below.
Guardian has not provided a quantitative reconciliation of forecasted adjusted EBITDA, which is a non-GAAP financial measure, to forecasted net income within this release because Guardian is unable, without making unreasonable efforts, to calculate certain reconciling items with confidence due to the variability and complexity of such items. These items include, but are not limited to, income taxes and share-based compensation. These items, which could materially affect the computation of forecasted net income, are inherently uncertain and depend on various factors that are not estimable at this time.
GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
| December 31, | ||||||||
| (In thousands, except share amounts) | 2024 | 2025 | ||||||
| Assets |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 4,660 | $ | 65,619 | ||||
| Accounts receivable, net |
97,153 | 101,614 | ||||||
| Inventories |
40,550 | 43,359 | ||||||
| Other current assets |
9,622 | 11,042 | ||||||
|
|
|
|
|
|||||
| Total current assets |
151,985 | 221,634 | ||||||
| Property and equipment, net |
49,883 | 55,522 | ||||||
| Intangible assets, net |
14,912 | 18,475 | ||||||
| Goodwill |
69,296 | 79,743 | ||||||
| Operating lease right-of-use assets |
29,079 | 34,649 | ||||||
| Deferred tax assets |
5,272 | 2,199 | ||||||
| Other assets |
383 | 436 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 320,810 | $ | 412,658 | ||||
|
|
|
|
|
|||||
| Liabilities and equity |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 102,420 | $ | 116,206 | ||||
| Accrued compensation |
14,430 | 15,048 | ||||||
| Operating leases, current portion |
6,836 | 7,150 | ||||||
| Other current liabilities |
20,435 | 22,299 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
144,121 | 160,703 | ||||||
| Operating leases, net of current portion |
23,297 | 29,992 | ||||||
| Other liabilities |
3,416 | 4,039 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
$ | 170,834 | $ | 194,734 | ||||
|
|
|
|
|
|||||
| Commitments and contingencies (see Note 9) |
||||||||
| Equity: |
||||||||
| Members’ equity |
— | — | ||||||
| Class A common stock- 700,000,000 shares authorized, par value $0.001; 9,200,000 and 36,253,744 shares issued and outstanding as of December 31, 2024 and December 31, 2025, respectively |
9 | 36 | ||||||
| Class B common stock- 100,000,000 shares authorized, par value $0.001; 54,087,158 and 27,066,890 shares issued and outstanding as of December 31, 2024 and December 31, 2025, respectively |
54 | 27 | ||||||
| Additional paid-in capital |
125,484 | 139,353 | ||||||
| Retained earnings |
17,124 | 66,343 | ||||||
| Non-controlling interests |
7,305 | 12,165 | ||||||
|
|
|
|
|
|||||
| Total equity |
149,976 | 217,924 | ||||||
|
|
|
|
|
|||||
| Total liabilities and equity |
$ | 320,810 | $ | 412,658 | ||||
|
|
|
|
|
|||||
GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
| Three Months Ended December 31, |
Year Ended December 31, |
|||||||||||||||
| (In thousands, except share and per share amounts) | 2024 | 2025 | 2024 | 2025 | ||||||||||||
| Revenues |
$ | 338,569 | $ | 397,616 | $ | 1,228,409 | $ | 1,448,685 | ||||||||
| Cost of goods sold |
271,465 | 312,114 | 984,038 | 1,155,967 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Gross profit |
67,104 | 85,502 | 244,371 | 292,718 | ||||||||||||
| Selling, general, and administrative expenses |
50,349 | 54,740 | 307,291 | 220,017 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Operating income (loss) |
16,755 | 30,762 | (62,920 | ) | 72,701 | |||||||||||
| Other expenses (income): |
||||||||||||||||
| Interest expense |
421 | 163 | 3,278 | 665 | ||||||||||||
| Other expense (income), net |
113 | (500 | ) | 279 | (1,387 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total other expenses (income) |
534 | (337 | ) | 3,557 | (722 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| — | ||||||||||||||||
| Income (loss) before income taxes |
16,221 | 31,099 | (66,477 | ) | 73,423 | |||||||||||
| Provision for income taxes |
4,380 | 9,834 | 4,556 | 24,465 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income (loss) |
11,841 | 21,265 | (71,033 | ) | 48,958 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Less net income attributable to Guardian Pharmacy, LLC prior to the Corporate Reorganization |
— | 22,760 | — | |||||||||||||
| Less net income (loss) attributable to non-controlling interests |
(102 | ) | 342 | 16,254 | (261 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income (loss) attributable to Guardian Pharmacy Services, Inc. |
$ | 11,943 | $ | 20,923 | $ | (110,047 | ) | $ | 49,219 | |||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income (loss) per share of Class A and Class B common stock |
||||||||||||||||
| Basic |
$ | 0.19 | $ | 0.33 | $ | (1.77 | ) | $ | 0.79 | |||||||
| Diluted |
$ | 0.19 | $ | 0.33 | $ | (1.77 | ) | $ | 0.78 | |||||||
| Weighted-average Class A and Class B common shares outstanding |
||||||||||||||||
| Basic |
62,043,311 | 63,320,634 | 62,005,811 | 62,386,253 | ||||||||||||
| Diluted |
62,724,108 | 63,617,708 | 62,005,811 | 63,297,123 | ||||||||||||
GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year Ended December 31, | ||||||||
| (In thousands) | 2024 | 2025 | ||||||
| Operating activities |
||||||||
| Net income (loss) |
$ | (71,033 | ) | $ | 48,958 | |||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: |
||||||||
| Depreciation and amortization |
19,772 | 22,335 | ||||||
| Share-based compensation expense |
131,490 | 13,850 | ||||||
| Provision for losses on accounts receivable |
6,370 | 4,581 | ||||||
| Change in deferred tax asset |
— | 3,074 | ||||||
| Other |
767 | 1,075 | ||||||
| Changes in operating assets and liabilities: |
||||||||
| Accounts receivable |
(25,485 | ) | (8,553 | ) | ||||
| Inventories |
(1,151 | ) | (877 | ) | ||||
| Other current assets |
(1,979 | ) | (2,482 | ) | ||||
| Accounts payable |
13,230 | 16,398 | ||||||
| Accrued compensation |
(2,967 | ) | 618 | |||||
| Other operating liabilities |
(11,054 | ) | 1,316 | |||||
|
|
|
|
|
|||||
| Net cash provided by operating activities |
57,960 | 100,293 | ||||||
| Investing activities |
||||||||
| Purchases of property and equipment |
(16,368 | ) | (19,583 | ) | ||||
| Payment for acquisitions |
(14,710 | ) | (13,416 | ) | ||||
| Other |
671 | 736 | ||||||
|
|
|
|
|
|||||
| Net cash used in investing activities |
(30,407 | ) | (32,263 | ) | ||||
| Financing activities |
||||||||
| Proceeds from equity offering, net of underwriter fees |
119,784 | 29,039 | ||||||
| Repurchase of outstanding Class A common stock |
— | (29,039 | ) | |||||
| Payments of equity offering costs |
(4,157 | ) | (1,594 | ) | ||||
| Payments to Class B common stock stockholders |
(55,176 | ) | — | |||||
| Borrowings from notes payable |
15,000 | — | ||||||
| Repayment of notes payable |
(38,000 | ) | (497 | ) | ||||
| Borrowings from line of credit |
189,300 | — | ||||||
| Repayments of line of credit |
(198,300 | ) | — | |||||
| Principal payments on finance lease obligations |
(4,481 | ) | (4,483 | ) | ||||
| Payments related to acquisitions |
— | (2,509 | ) | |||||
| Contributions from non-controlling interests |
2,758 | 1,970 | ||||||
| Distributions to non-controlling interests |
(14,463 | ) | (458 | ) | ||||
| Member distributions |
(35,750 | ) | — | |||||
| Other |
(160 | ) | 500 | |||||
|
|
|
|
|
|||||
| Net cash used in financing activities |
(23,645 | ) | (7,071 | ) | ||||
| Net change in cash and cash equivalents |
3,908 | 60,959 | ||||||
| Cash and cash equivalents, beginning of period |
752 | 4,660 | ||||||
|
|
|
|
|
|||||
| Cash and cash equivalents, end of period |
$ | 4,660 | $ | 65,619 | ||||
|
|
|
|
|
|||||
| Supplemental disclosure of cash flow information |
||||||||
| Cash paid during the year for interest |
$ | 3,121 | $ | 650 | ||||
|
|
|
|
|
|||||
| Cash paid during the year for income taxes |
$ | — | $ | 21,541 | ||||
|
|
|
|
|
|||||
| Supplemental disclosure of non-cash investing and financing activities |
||||||||
| Purchases of property and equipment through finance leases |
$ | 3,529 | $ | 4,941 | ||||
|
|
|
|
|
|||||
| Accrued and capitalized offering costs recorded to additional paid-in capital |
$ | 8,866 | $ | — | ||||
|
|
|
|
|
|||||
| Non-cash equity contributions from non-controlling members |
$ | 5,604 | $ | 3,609 | ||||
|
|
|
|
|
|||||
GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP GAAP FINANCIAL MEASURES
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| (in thousands) | 2024 | 2025 | 2024 | 2025 | ||||||||||||
| Net income (loss) |
$ | 11,841 | 21,265 | $ | (71,033 | ) | 48,958 | |||||||||
| Add: |
||||||||||||||||
| Interest expense (income), net |
421 | (215 | ) | 3,278 | (418 | ) | ||||||||||
| Depreciation and amortization |
5,153 | 5,741 | 19,772 | 22,335 | ||||||||||||
| Provision for income taxes |
4,380 | 9,834 | 4,556 | 24,465 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| EBITDA |
$ | 21,795 | $ | 36,625 | $ | (43,427 | ) | $ | 95,340 | |||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Share-based compensation (1) |
3,461 | 1,080 | 131,490 | 13,850 | ||||||||||||
| Certain legal & other regulatory matters (2) |
181 | 37 | 3,988 | 1,094 | ||||||||||||
| Financing-related and other activities (3) |
453 | 251 | 453 | 2,175 | ||||||||||||
| Payor-reimbursement matters (4) |
— | $ | 1,493 | (1,670 | ) | $ | 2,686 | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted EBITDA |
$ | 25,890 | $ | 39,486 | $ | 90,834 | $ | 115,145 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income as a percentage of revenue |
3.5 | % | 5.3 | % | (5.8 | )% | 3.4 | % | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted EBITDA as a percentage of revenue |
7.6 | % | 9.9 | % | 7.4 | % | 7.9 | % | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net Income (loss) attributable to Guardian Pharmacy Services, Inc. |
11,943 | 20,923 | (110,047 | ) | 49,219 | |||||||||||
| Share-based compensation (1) |
3,461 | 1,080 | N/M | 13,850 | ||||||||||||
| Certain legal & other regulatory matters (2) |
181 | 37 | N/M | 1,094 | ||||||||||||
| Financing-related and other activities (3) |
453 | 251 | N/M | 2,175 | ||||||||||||
| Payor-reimbursement matters (4) |
— | 1,493 | N/M | 2,686 | ||||||||||||
| Acquisition-related intangible asset amortization (5) |
868 | 971 | N/M | 3,658 | ||||||||||||
| Income tax impact of adjustments (7) |
(1,340 | ) | (1,115 | ) | N/M | (6,969 | ) | |||||||||
| Certain tax matters related to Corporate Reorganization and IPO (6) |
— | — | — | 1,725 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted net income |
$ | 15,566 | $ | 23,640 | N/M | (8) | $ | 67,438 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Weighted average common shares outstanding used in calculating diluted U.S. GAAP net income per share |
62,724,108 | 63,617,708 | N/A | 63,297,123 | ||||||||||||
| Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per share |
62,724,108 | 63,617,708 | N/M | 63,297,123 | ||||||||||||
| Diluted EPS |
$ | 0.19 | $ | 0.33 | (1.77 | ) | $ | 0.78 | ||||||||
| Adjusted EPS |
0.25 | $ | 0.37 | N/M | (8) | $ | 1.07 | |||||||||
| GAAP selling, general, and administrative expenses |
50,349 | $ | 54,740 | 307,291 | 220,017 | |||||||||||
| Subtract: |
||||||||||||||||
| Share-based compensation (1) |
3,461 | 1,080 | 131,490 | 13,850 | ||||||||||||
| Certain legal & other regulatory matters (2) |
181 | 37 | 3,988 | 1,094 | ||||||||||||
| Financing-related and other activities (3) |
453 | 251 | 453 | 2,175 | ||||||||||||
| Payor-reimbursement matters (4) |
$ | — | 1,493 | $ | — | 4,316 | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted SG&A |
$ | 46,254 | $ | 51,879 | $ | 171,360 | $ | 198,582 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| GAAP selling, general, and administrative expenses as a percentage of revenue |
14.9 | % | 13.8 | % | 25.0 | % | 15.2 | % | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted SG&A as a percentage of revenue |
13.7 | % | 13.0 | % | 13.9 | % | 13.7 | % | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| (1) | Prior to the Corporate Reorganization and IPO, our share-based compensation expense primarily represented non-cash recognition of changes in the value of Restricted Interest Unit awards, which had historically been recorded as a liability using a cash settlement methodology as calculated on a quarterly basis. In connection with the Corporate Reorganization and IPO, certain Restricted Interest Unit awards were modified, resulting in incremental share-based compensation expense of $125.7 million during the year ended December 31,2024, based on the fair value of the modified awards. Share-based compensation expense subsequent to the Corporate Reorganization and IPO and for the year ended December 31, 2025 relates to equity-classified awards. |
| (2) | Represents non-recurring attorney’s fees, settlement costs and other expenses associated with certain legal proceedings. The Company excludes such charges when evaluating operating performance because it does not incur such charges on a predictable basis and exclusion allows for consistent evaluation of operations. |
| (3) | Represents non-recurring costs associated with various financing-related activities and costs to transition to a public company. |
| (4) | Represents non-recurring proceeds, recorded as revenue, and legal expenses, recorded as selling, general and administrative expenses, associated with payor reimbursement matters. |
Proceeds received associated with payor reimbursement matters, recorded as revenue, were $0.0 million and $1.6 million during the three months and year ended December 31, 2025, respectively, and $0.0 million and $1.7 million during the three months and year ended December 31, 2024, respectively.
Legal expenses associated with payor reimbursement matters, recorded as selling, general and administrative expenses, during the three months and year ended December 31, 2025 were $1.5 million and $4.3 million, respectively and $0.0 million during the three months and year ended December 31, 2024.
| (5) | Represents amortization expense associated with the acquisition-related intangible assets, such as customer lists and trademarks. |
| (6) | Represents non-recurring income tax expense associated with the Corporate Reorganization and IPO. The Company excludes such charges when evaluating operating performance because it does not incur such charges on a predictable basis and exclusion allows for consistent evaluation of operations. |
| (7) | Represents the income tax impact of non-GAAP adjustments, calculated using the estimated tax rate for the respective non-GAAP adjustment. |
| (8) | Adjusted net income and Adjusted EPS are not presented for the year ended December 31, 2024, as the net income attributable to Guardian Pharmacy Services, Inc. during that period only includes net income for the period subsequent to our IPO on September 27, 2024. As such, adjusted net income and adjusted EPS are not meaningful for these periods. |
FAQ
How did Guardian Pharmacy Services (GRDN) perform financially in 2025?
What 2026 guidance did Guardian Pharmacy Services (GRDN) provide?
How strong is Guardian Pharmacy Services’ (GRDN) balance sheet and liquidity?
What operational milestones did Guardian Pharmacy Services (GRDN) highlight for 2025?
How are Guardian Pharmacy Services’ (GRDN) vaccine clinics performing?
What non-GAAP measures does Guardian Pharmacy Services (GRDN) use and why?
How might regulatory and pricing changes affect Guardian Pharmacy Services (GRDN)?
Filing Exhibits & Attachments
4 documents